JAMP ELTROMBOPAG DIN 02572591
Health Canada record
| Active ingredient(s) | ELTROMBOPAG (ELTROMBOPAG OLAMINE) 25 MG |
|---|---|
| Dosage form | Tablet |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | B02BX05 ELTROMBOPAG |
| Original market date | |
| Current status date | 09-Oct-2026 |
| Source | Health Canada DPD |
Establishment licence of the holder
Jamp Pharma Corporation — licence 100590, currently licensed, last inspection rating I (2026-09-16).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing ELTROMBOPAG (ELTROMBOPAG OLAMINE)
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02506742 | APO-ELTROMBOPAG | APOTEX INC | Tablet | ELTROMBOPAG (ELTROMBOPAG OLAMINE) 25 MG | Marketed |
| 02506769 | APO-ELTROMBOPAG | APOTEX INC | Tablet | ELTROMBOPAG (ELTROMBOPAG OLAMINE) 50 MG | Marketed |
| 02572605 | JAMP ELTROMBOPAG | JAMP PHARMA CORPORATION | Tablet | ELTROMBOPAG (ELTROMBOPAG OLAMINE) 50 MG | Approved |
| 02361833 | REVOLADE | NOVARTIS PHARMACEUTICALS CANADA INC | Tablet | ELTROMBOPAG (ELTROMBOPAG OLAMINE) 50 MG | Marketed |
| 02361825 | REVOLADE | NOVARTIS PHARMACEUTICALS CANADA INC | Tablet | ELTROMBOPAG (ELTROMBOPAG OLAMINE) 25 MG | Marketed |
| 02551748 | TEVA-ELTROMBOPAG | TEVA CANADA LIMITED | Tablet | ELTROMBOPAG (ELTROMBOPAG OLAMINE) 50 MG | Approved |
| 02551721 | TEVA-ELTROMBOPAG | TEVA CANADA LIMITED | Tablet | ELTROMBOPAG (ELTROMBOPAG OLAMINE) 25 MG | Approved |
| 02461382 | REVOLADE | NOVARTIS PHARMACEUTICALS CANADA INC | Tablet | ELTROMBOPAG (ELTROMBOPAG OLAMINE) 12.5 MG | Cancelled Pre Market |
| 02423049 | REVOLADE | NOVARTIS PHARMACEUTICALS CANADA INC | Tablet | ELTROMBOPAG (ELTROMBOPAG OLAMINE) 75 MG | Cancelled Pre Market |